asx announcement, page-38

  1. 261 Posts.
    The only thing I see is that they want Xtoll, but their exprience and expertise seems to be with chest and heart not anti-inflammatory conditions. This was why Novo wanted Xtoll as that is what they specialse in.
    Other reason could be to offset risk, pickup access to easy money, rope in a few more aussies for the risk. I imagine investors a very nervous in US, so might be hard to get funds.
    Think CBIO looses 37% in the deal, and they get a chance that they get a drug that might or might not be a winner in about 3 to 5 years.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.